
"A Registry of Caris Target Now™ Test Results (Biomarker Expression Patterns) and Hematopoietic Diagnostics for Evaluation of Correlation with Clinical Outcomes for Cancer and other Patients" is a multi-center, observational outcomes database designed to collect data on the demographics, presentation, diagnosis, treatment, resource use, and outcomes of eligible patients who previously have undergone; 1) Caris Target Now™ testing for treatment of solid tumor cancer and/or 2) Caris hematopoietic diagnostics testing for diagnosis of hematopoietic malignancies and blood anomalies. Participation guidelines have been separately determined by the registry team, pursuant to a Protocol which has been approved by an independent Institutional Review Board (IRB).
The registry is a mechanism by which eligible patients can choose to participate through their physicians in cancer and blood dyscrasias research. By contributing patients' data, physicians and patients gain the knowledge that future patients with similar disease profiles may benefit from the experiences of the patients that contributed information before them.
Eligibility:
Participation in the registry is voluntary. All patients seen within a participating physician practice are potential candidates for this registry given they further meet the eligibility criteria requirements as follows:
Inclusion criteria:
For more information:
Caris Target Now™ was developed and its performance characteristics were determined by Caris Life Sciences, a medical laboratory CLIA-certified in compliance with the U.S. Clinical Laboratory Amendment Act of 1988 and all relevant U.S. state regulations. It has not been approved by the United States Food and Drug Administration.